EyePoint dosed first patient in second Phase 3 wet AMD trial (LUCIA); topline data expected 2026

EyePoint, Inc.

First patient dosed in LUCIA, the second global Phase 3 trial of DURAVYU (vorolanib Durasert E) for wet AMD.
LUCIA follows LUGANO trial; both are randomized, double-masked, non-inferiority vs aflibercept with ~400 patients each.
Primary endpoint: average change in BCVA at weeks 52 and 56; re-dosing every six months.
Topline data from Phase 3 pivotal program anticipated in 2026; over 240 global sites committed.
CEO cites robust interest and strong balance sheet; LUGANO enrollment exceeded expectations.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.